aminostigmine and Cognition-Disorders

aminostigmine has been researched along with Cognition-Disorders* in 1 studies

Other Studies

1 other study(ies) available for aminostigmine and Cognition-Disorders

Article	Year
Possibility of usage of aminostigmine structural analogue for the treatment of toxic cognitive disorders. Bulletin of experimental biology and medicine, 2014, Volume: 156, Issue:3 We studied the effects of 2-(hexyl(methyl)amino)methyl)pyridyl-3-dimethyl carbamate (OPDC), a structural analogue of aminostigmine oxalate, on memory formation in rats with toxic scopolamine-induced amnesia. It was shown that OPDC in non-toxic doses ((1)/215 LD50) has significant anti-amnesic action. Ipidacrine and galantamine in the doses similar to toxic doses ((1)/17 and (1)/6 of LD50, respectively) induced the retention of memory trace. Administration of aminostigmine ((1)/11 of LD50) induced unstable anti-amnesic effect in the model of scopolamine-induced amnesia. Topics: Animals; Carbamates; Cognition Disorders; Lethal Dose 50; Male; Pyridostigmine Bromide; Rats	2014

Article

Year

Possibility of usage of aminostigmine structural analogue for the treatment of toxic cognitive disorders.

Bulletin of experimental biology and medicine, 2014, Volume: 156, Issue:3

We studied the effects of 2-(hexyl(methyl)amino)methyl)pyridyl-3-dimethyl carbamate (OPDC), a structural analogue of aminostigmine oxalate, on memory formation in rats with toxic scopolamine-induced amnesia. It was shown that OPDC in non-toxic doses ((1)/215 LD50) has significant anti-amnesic action. Ipidacrine and galantamine in the doses similar to toxic doses ((1)/17 and (1)/6 of LD50, respectively) induced the retention of memory trace. Administration of aminostigmine ((1)/11 of LD50) induced unstable anti-amnesic effect in the model of scopolamine-induced amnesia.

Topics: Animals; Carbamates; Cognition Disorders; Lethal Dose 50; Male; Pyridostigmine Bromide; Rats

2014